Akebia Therapeutics (AKBA) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 45.9% versus a loss of 72.3%. Over five years, AKBA leads with a -71.4% price change compared with -96.5% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $222.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | ZNTL |
|---|---|---|
| Share price | $0.8011 | $2.64 |
| Market cap | $221.99M | $259.04M |
| 1-day change | -1.68% | +5.18% |
| YTD return | -50.24% | +95.56% |
| 1-year return | -72.28% | +45.86% |
| 5-year return | -71.41% | -96.48% |
| EPS (TTM) | $-0.12 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $6.95 |
| 52-week low | $0.8011 | $1.21 |
| Distance from 52-week high | -74.97% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | +389.33% | +177.65% |
| Average volume | 6.18M | 1.21M |
| Shares outstanding | 277.11M | 98.12M |
| Employees | 194 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed AKBA by 118.1 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
AKBA vs ZNTL FAQ
Which is bigger, Akebia Therapeutics or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $221.99M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or ZNTL?
ZNTL returned +45.86% over the past 12 months, compared with -72.28% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.